Keros Therapeutics, Inc. KROS
Biotechnology: Pharmaceutical Preparations · IPO 2020 · data as of November 13, 2026
Keros Therapeutics, Inc. (KROS) is a healthcare company listed in the US with a market value of about $202M. In the twelve months to September 30, 2026 it had revenue of $41M and net income of -$62M, a net margin of -151.5%.
Its overall Stock Analiz score is 1.4 out of 5 (weak). The strongest part is future growth (3/5); the weakest is value (0/5).
Key numbers: a 5-year average ROIC of -23%.
About Keros Therapeutics
Keros Therapeutics is listed in the US and classified in biotechnology: pharmaceutical preparations, IPO year 2020. Revenue went from $10M in 2019 to $244M in 2025, growth of about 70.3% a year. It was profitable in 1 of the last 7 years in our data. Its share count rose by 50% over three years (dilution for shareholders). It spends 53% of revenue on research and development.
Score: 1.4 / 5
Checks passed
- Revenue growth above 10% last year
- Profit margin improving
- Strong R&D investment or growth above 20%
- ROE above 15%
- More cash than debt, or low debt to equity
- Interest covered more than 5 times
- Liabilities below 60% of assets
Checks not passed
- P/E below 25
- P/E below the industry median
- P/FCF below 20
- Price below intrinsic value (DCF, moderate assumptions)
- PEG below 1.5
- 3-year revenue growth above 10% a year
- 3-year free cash flow growth above 10% a year
- 5-year EPS growth above 10% a year
Valuation
Growth and quality
Financials, last 7 years
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $41M | $244M | $4M | $151000 | $0 | $20M | $0 | $10M |
| Net income | -$62M | $87M | -$187M | -$153M | -$105M | -$59M | -$45M | -$12M |
| Free cash flow | -$48M | $106M | -$163M | -$127M | -$71M | -$63M | -$37M | -$16M |
| EPS (diluted) | $-2.34 | $2.30 | $-5.00 | $-5.20 | $-4.15 | $-2.52 | $-2.93 | $-6.08 |
| Net margin | -151.5% | 35.7% | -5277.6% | -101300.0% | — | -292.3% | — | -123.4% |
| ROIC | — | 20.0% | -28.2% | -49.0% | -39.5% | -18.2% | -17.7% | — |
From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.
What analysts expect
The average 12-month price target from 6 analysts is $19.83, 93% above the current price; targets range from $16.00 to $25.00; the consensus rating is “Buy”; expected EPS is $-3.35 for the fiscal year ending December 31, 2026.
Frequently asked questions
Does Keros Therapeutics pay a dividend?
Not currently.
Is Keros Therapeutics a good stock to buy?
We do not give buy or sell advice. Keros Therapeutics scores 1.4 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.
Similar companies
Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.